linjc16/ctgov huggingface dataset:
Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients

Study Overview
=================
Brief Summary
-----------------
This research studies genes associated with non-Hodgkin lymphoma in young patients. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

Detailed Description
-----------------
OBJECTIVES: I. To conduct a preliminary investigation of the effects of loci strongly and consistently associated in prior genome-wide association studies (GWAS) and validation studies of childhood/adolescent acute lymphoblastic leukemia (ALL), adult non-Hodgkin lymphoma (NHL), autoimmune diseases, and atopic diseases on the risk of NHL (lymphoblastic and Burkitt lymphomas) in children and adolescents. OUTLINE: DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.

Official Title
-----------------
Observational - Candidate Gene Variants and Childhood/Adolescent Non-Hodgkin Lymphoma: A Preliminary Investigation

Conditions
-----------------
Childhood Burkitt Lymphoma, Childhood Lymphoblastic Lymphoma

Intervention / Treatment
-----------------
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Slides and/or other available specimens from patients diagnosed with lymphoblastic lymphoma (LL) or Burkitt lymphoma ( BL) enrolled on the Children Oncology Group (COG) protocols 5961, A5971, and ANHL01P1 collected at the time of diagnosis and currently housed at the Biopathology Center at Nationwide Children's Hospital Samples from non-Hispanic white patients DNA samples from 384 healthy, anonymous, non-Hispanic white blood donors used as controls See Disease Characteristics Not specified

Ages Eligible for Study
-----------------
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational<br>DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system. | Other: laboratory biomarker analysis<br>* Correlative studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Potential deviations from Hardy-Weinberg Equilibrium (HWE) |  | Baseline |
EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment

Study Overview
=================
Brief Summary
-----------------
This study has been designed in order to detect EGFR mutation abundance of tissue and concentration of plasma from Advanced Non-small Cell Lung Cancer during treatment with Tyrosine Kinase Inhibitor (TKI) .Through this experiment the investigators aim to evaluate the feasibility of plasma EGFR detection and evaluate the correlation of EGFR mutations and prognosis.

Official Title
-----------------
Epidermal Growth Factor Receptor (EGFR) Mutation Detection From Advanced Non-small Cell Lung Cancer Tissue and Plasma in Tyrosine Kinase Inhibitor (TKI) Treatment

Conditions
-----------------
Non-small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age older than 18 years and under 75 years Histologically and cytologically proven non-small Cell Lung Cancer Clinical stages Ⅲ   Ⅳ Not receive any anti-tumor treatment Eastern cooperative oncology group performance status (ECOG PS) =1 2 Estimated survival time more than 3 months EGFR-TKI treatment for first-line or second-line Voluntary to participate in this clinical trial and sign the consent form Exclusion Criteria: Patients have received EGFR-TKI therapy before the study With other malignancy history in the recent 5 years before the study Pregnancy or breast feeding phase Inadequate samples for testing Follow-up compliance is poor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients advanced NSCLC EGFR mutated<br>This is an observational study, there is no intervention. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EGFR Mutation Detection of FFPE and plasma samples | To evaluate the feasibility of plasma EGFR detection from non-small cell lung cancer patients harboring EGFR activating mutation who are being treated with EGFR TKIs and evaluate the correlation of EGFR mutations and prognosis. | baseline | 
| EGFR Mutation Detection of plasma samples for the following-up patients who take TKI. | In order to monitor the change of plasma EGFR mutation copy number. | From start of treatment to time of progression or death, whichever occurs first, assessed up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epidermal growth factor receptor(EGFR), NSCLC
Independent Predictors Analysis and Model Construction of Cavitary Central Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective, multicenter clinical study. The main goal is to identify the risk factors for cavity formation in central-type lung cancer lesions, and to construct a prediction model for cavity formation in central-type lung cancer lesions based on the above risk factors.

Official Title
-----------------
Independent Predictors Analysis and Model Construction of Cavitary Central Lung Cancer: a Retrospective, Multicenter Trial

Conditions
-----------------
Central Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age：older than 18 years； Clinical or pathologically confirmed central lung cancer; Lesions without cavities at first diagnosis of central lung cancer; Performed complete laboratory and imaging research at the first diagnosis of the central lung cancer; Patients with cavities formation during follow up, and the cavities were independently confirmed by at least 3 imaging experts; Patients with complete medical records; Exclusion Criteria: Patients suffering other malignant tumors; Patients missing the imaging data; Patients missing the clinical data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Formation of cavities in the central lung cancer, assessed up to 18 months. | Time from enrollment to the time of cavities formation, assessed up to 18 months. | Time from enrollment to the time of cavities formation, assessed up to 18 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoptysis in patients with central lung cancer, assessed up to 18 months. | Time from enrollment to hemoptysis, assessed up to 18 months. | Time from enrollment to hemoptysis, assessed up to 18 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Central Lung Cancer, Cavity, Predictor
Cicatrix Cream in Cutaneous Groves

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to assess the effect of CICATRIX (Asian Gotu Kola or Pennywort) usage in the treatment of cutaneous grooves. The duration of this phase 2 clinical trial will be 4 months.

Official Title
-----------------
Effect the Cicatrix Cream in Cutaneous Groves Treatment

Conditions
-----------------
Cutaneous Groves

Intervention / Treatment
-----------------
* Other: Cicatrix cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent Exclusion Criteria: Patient that refer manifestations of high sensibility to the medication or to some of the components of the product. Patient that don't want to participate in the study. Patient not very cooperative. Responsible family not very cooperative.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Cicatrix cream | Other: Cicatrix cream<br>* We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations. The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| They are the cutaneous grooves, being Observed the reduction of the number of the lesions monthly. |  | 4 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extension of the groves and the reduction of these expressed in centimetres |  | 4 months | 
| Adverse effects |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cutaneous Groves
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of BETOPTIC S and Timolol Gel-forming solution in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients will have a dilated fundus exam and corneal measurements taken at first and last visit.

Official Title
-----------------
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Conditions
-----------------
Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: BETOPTIC S (betaxolol HCl)
* Drug: Timolol Gel-forming Solution (TGFS)


Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION: Children 5 years old and younger require treatment for glaucoma or ocular hypertension whose vision is 20/80 or better have a cup-to-disc ratio of 0.8 or less EXCLUSION: do not have abnormal fixation IOP greater than 36 mm Hg significant retinal disease penetrating keratoplasty severe ocular pathology optic atrophy eye surgery in the past 30 days cardiovascular abnormalities hypersensitivity to beta blockers

Ages Eligible for Study
-----------------
Minimum Age: 1 Week
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Betaxolol<br>Two doses daily for 12 weeks | Drug: BETOPTIC S (betaxolol HCl)<br>* betaxolol HC)<br>|
| Experimental: TGFS 0.25%<br>Two doses daily for 12 weeks | Drug: Timolol Gel-forming Solution (TGFS)<br>* timolol maleate 0.25% and 0.5%<br>|
| Experimental: TGFS 0.5%<br>Two doses daily for 12 weeks | Drug: Timolol Gel-forming Solution (TGFS)<br>* timolol maleate 0.25% and 0.5%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline in IOP |  | Up to Week 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Ocular Hypertension
Biomarkers of Insomnia and Fatigue in HIV/AIDS (Symptoms and Genetics Study)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify biological markers, including genes, associated with sleep disturbance and other symptoms among people with HIV.

Detailed Description
-----------------
This study will characterize insomnia subtypes and identify genetic markers and metabolic parameters associated with these subtypes. The results will be useful in later developing interventions to improve sleep, reduce fatigue, and thereby enhance the quality of life of HIV-infected persons. A cross-sectional sample of 350 subjects will be recruited to describe relationships between biomarkers and insomnia subtypes. The initial assessment will include: wearing a wrist actigraph for 72 hours providing a fasting blood sample measuring blood pressure, height, weight, neck, waist, hip, and thigh completing questionnaires urine screening Depending on the results of the initial assessment, approximately 200 subjects will be followed every month by telephone to assess symptoms and every 3 to 6 months with study visits similar to the initial assessment. Findings from this longitudinal part of the study will characterize the development of insomnia, fatigue, and daytime sleepiness over time in patients living with HIV.

Official Title
-----------------
Biomarkers of Insomnia and Fatigue in HIV/AIDS

Conditions
-----------------
HIV Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV infection Access to a telephone Able to read and write English Exclusion Criteria: Current use of illicit drugs Currently pregnant or within the previous 3 months Working nightshift Diagnosis of sleep apnea, narcolepsy, restless legs syndrome, or periodic limb movements, dementia, or psychotic illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep disorders, genetics
Measurements to Assess Severity of Epicardial Stenoses

Study Overview
=================
Brief Summary
-----------------
Newly developed diagnostic parameters have potential to differentiate between epicardial disease and microvascular dysfunction with the help of anatomical details and physiological endpoints and can be used in present clinical settings.

Detailed Description
-----------------
The pressure drop coefficient (CDP) is a functional index based on hyperemic dp and u measurements. The lesion flow coefficient (LFC) combines the functional index CDP with an atomic measure (percentage area stenosis) as a single parameter.

Official Title
-----------------
Simultaneous Measurements Of Pressure Gradient, Blood Flow and Percentage Area Stenosis Of Coronary Epicardial Lesions To Assess Severity Of Epicardial Stenosis And Myocardial Infarction

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: FFR/CFR and IVUS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Abnormal Myocardial stress perfusion (SPECT) LV EF > 25% Exclusion Criteria: LV < or + to 25% Serum Creatinine > 2.5 gm/dL Type II HIT Significant co-morbidities Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CDP LFC<br>all patients will have this calculation based upon diagnostic parameters with IVUS and FFR and/or CFR | Device: FFR/CFR and IVUS<br>* All patients with clinical indication for cardiac cath will have FFR and IVUS<br>* Other names: Volcano FFR and IVUS catheters will be used;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to detect ischemic heart disease in patients with abnormal stress tests using MPI with SPECT and to determine the presence of significant epicardial stenosis using coronary angiography with simultaneous physiological pressure and flow measurements |  | Upon Diagnostic Angiogram and Flow Wire | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare novel measurements, Pressure Drop Coefficient (CDP) & Lesion Flow Coefficient (LFC), against measured current parameters called Fractional flow reserve (FFR) & Coronary flow reserve (CFR). |  | Upon Diagnostic Angiogram and Flow Wire | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
abnormal stress test, fractional flow reserve, pressure drop coefficient, lesion flow coefficient
Heliox in Preterm Infants With Respiratory Distress Syndrome

Study Overview
=================
Brief Summary
-----------------
Heliox can lower respiratory resistance, improve the oxygenation, reduce respiratory distress and lung injury caused by mechanical ventilation.

Detailed Description
-----------------
Heliox can improve the oxygenation, reduce respiratory distress and lung injury caused by mechanical ventilation. Heliox has not been widely used. More studies on the effects and safety of Heliox in addition to NIPPV and mechanical ventilation should be tried.

Official Title
-----------------
Nasal Intermittent Positive Pressure Ventilation and Mechanical Ventilation With Heliox in Preterm Infants With Respiratory Distress Syndrome

Conditions
-----------------
Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Other: heliox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational age more than 28 weeks and less than 32 weeks Diagnosed as respiratory distress syndrome Need to use NIPPV ventilation No congenital diseases or hereditary diseases With an informed consent form Exclusion Criteria: With congenital diseases or hereditary diseases Intubated in the delivery room Need surgery

Ages Eligible for Study
-----------------
Minimum Age: 28 Weeks
Maximum Age: 37 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: heliox<br>Heliox is use in this group | Other: heliox<br>* heliox or oxygen is used in the two groups respectively<br>|
| Placebo Comparator: Placebo<br>Oxygen is used in this group | Other: heliox<br>* heliox or oxygen is used in the two groups respectively<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of ventilation and risk of mechanical ventilation | The primary outcome is the length of ventilation and risk of mechanical ventilation of participants. | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Transcutaneous blood gas analysis，ventilator parameters and lung inflammation cytokines |  | participants will be followed for the duration of hospital stay, an expected average of 2 weeks |